Hepatitis D - Market Insights, Epidemiology and Market Forecast-2027

  • ID: 4520740
  • Drug Pipelines
  • 135 pages
  • DelveInsight
1 of 4

FEATURED COMPANIES

  • Eiger BioPharmaceuticals
  • Hoffmann-La Roche
  • MYR Pharma
  • Replicor Inc.
  • MORE
This report titled ‘Hepatitis D - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Hepatitis D in the United States, EU5 (France, Germany, Italy, Spain and United Kingdom), Japan and China.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Hepatitis D from 2016 to 2027 segmented by eight major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to find best of the opportunities and assess underlying potential of the market.

Geography Covered:
  • The United States
  • EU5 (France, Germany, Italy, Spain and the United Kingdom)
  • Japan
  • China
Study Period: 2016-2027

Hepatitis D - Disease Understanding and Treatment Algorithm:

The Hepatitis D market report gives the thorough understanding of Hepatitis D by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Hepatitis D in the US, Europe and Japan and China.

Hepatitis D Epidemiology:

The Hepatitis D epidemiology division provide the insights about historical and current patient pool and forecasted trend for each of the 8 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [total prevalent cases, prevalence by Severity (Fulminant, Acute & Chronic), Gender Specific prevalence, Age Specific prevalence and diagnosed cases] of Hepatitis-D in the 8MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), Japan and China from 2016-2027.
According to this research, total prevalent population of Hepatitis D in 8 major markets was estimated to be 10,546,938 in 2016.

Hepatitis D Drug Chapters:

This segment of Hepatitis D report encloses the detailed analysis of marketed drugs and late stage (Phase-III & Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

There is no cure or vaccine for Hepatitis D and the current market is based on the use of antiviral nucleotide analogs, conventional interferon and off-label use of pegylated Interferon. There is not much progress in treatment methods for Hepatitis D after Interferons, only off-label use of pegylated Interferon has reduced the doses of conventional interferon from thrice a week to once a week. To overcome the shortcomings of current treatment market different companies are working robustly with promising drug candidates in different target areas to bring an effective therapy to the market.
Detailed chapters for all the upcoming therapies i.e., Pegasys (Hoffmann-La Roche), Pegylated interferon lambda 1a (Eiger Biopharmaceuticals Inc.), Myrcludex B (MYR Pharma), Lonafarnib (Eiger Bio-Pharmaceuticals), REP 2139-Ca (Replicor Inc.) etc., have been covered in the report.

Hepatitis D Market Outlook:

The Hepatitis D market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of off-label therapies, marketed therapies and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to this research, the global market of Hepatitis D was estimated to be USD 656 Million in 2016, and is expected to increase from 2016-2027.

Hepatitis D Drugs Uptake:

This section focusses on the rate of uptake of the potential drugs that will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Hepatitis D Report Insights:
  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Hepatitis D Report Key Strengths:
  • 10 Year Forecast
  • 8MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analysed Market
  • Key Cross Competition
Hepatitis D Report Assessment:
  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Benefits:
  • This report will help to develop Business Strategies by understanding the trends shaping and driving the Hepatitis D market
  • Organize sales and marketing efforts by identifying the best opportunities for Hepatitis D market
  • To understand the future market competition in the Hepatitis D market.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Eiger BioPharmaceuticals
  • Hoffmann-La Roche
  • MYR Pharma
  • Replicor Inc.
  • MORE
1. Key Insights

2. Hepatitis D Market Overview at a Glance
2.1. Market Share (%) Distribution of Hepatitis D in 2017
2.2. Market Share (%) Distribution of Hepatitis D in 2027

3. Disease Background and Overview: Hepatitis D
3.1. Introduction
3.2. Classification
3.3. Factors influencing Hepatitis D Progression
3.4. Disease Causes
3.5. HDV-Symptoms
3.6. Pathogenesis
3.7. Pathophysiology
3.8. HDV Diagnosis
3.9. Prevention

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 8MM Prevalent Population of Hepatitis D

5. Country Wise-Epidemiology of Hepatitis D
5.1. United States
5.1.1. Prevalent cases of Hepatitis D in the United States
5.1.2. Prevalent Population of Hepatitis D by severity
5.1.3. Gender Specific Hepatitis D Prevalence
5.1.4. Age Specific Hepatitis D Prevalence
5.1.5. Diagnosed cases of Chronic Hepatitis D
5.2. EU5
5.2.1. Prevalent Population of Hepatitis D in EU5
5.3. France
5.3.1. Prevalent Population of Hepatitis D
5.3.2. Prevalent Population of Hepatitis D by severity
5.3.3. Gender Specific Hepatitis D Prevalence
5.3.4. Age Specific Hepatitis D Prevalence
5.3.5. Diagnosed cases of Chronic Hepatitis D
5.4. Germany
5.4.1. Prevalent Population of Hepatitis D
5.4.2. Prevalent Population of Hepatitis D by severity
5.4.3. Gender Specific Hepatitis D Prevalence
5.4.4. Age Specific Hepatitis D Prevalence
5.4.5. Diagnosed cases of Chronic Hepatitis D
5.5. Italy
5.5.1. Prevalent Population of Hepatitis D
5.5.2. Prevalent Population of Hepatitis D by severity
5.5.3. Gender Specific Hepatitis D Prevalence
5.5.4. Age Specific Hepatitis D Prevalence
5.5.5. Diagnosed cases of Chronic Hepatitis D
5.6. Spain
5.6.1. Prevalent Population of Hepatitis D
5.6.2. Prevalent Population of Hepatitis D by severity
5.6.3. Gender Specific Hepatitis D Prevalence
5.6.4. Age Specific Hepatitis D Prevalence
5.6.5. Diagnosed cases of Chronic Hepatitis D
5.7. United Kingdom
5.7.1. Prevalent Population of Hepatitis D
5.7.2. Prevalent Population of Hepatitis D by severity
5.7.3. Gender Specific Hepatitis D Prevalence
5.7.4. Age Specific Hepatitis D Prevalence
5.7.5. Diagnosed cases of Chronic Hepatitis D
5.8. Japan
5.8.1. Prevalent Population of Hepatitis D
5.8.2. Prevalent Population of Hepatitis D by severity
5.8.3. Gender Specific Hepatitis D Prevalence
5.8.4. Age Specific Hepatitis D Prevalence
5.8.5. Diagnosed cases of Chronic Hepatitis D
5.9. China
5.9.1. Prevalent Population of Hepatitis D
5.9.2. Prevalent Population of Hepatitis D by severity
5.9.3. Gender Specific Hepatitis D Prevalence
5.9.4. Age Specific Hepatitis D Prevalence
5.9.5. Diagnosed cases of Chronic Hepatitis D

6. Current Treatment Practices

7. Treatment Algorithm

8. Unmet needs

9. Emerging Therapies
9.1. Key Cross Competition
9.2. Phase II Drugs
9.3. Pegasys: Hoffmann-La Roche
9.3.1. Drug Description
9.3.2. Product Profile
9.3.3. Clinical Development
9.3.4. Clinical Trials Information
9.3.5. Safety and efficacy
9.3.6. Advantages and Disadvantages
9.4. REP 2139-Ca + Pegasys: Replicor Inc.
9.4.1. Drug Description
9.4.2. Product Profile
9.4.3. Other Development Activities
9.4.4. Clinical Development
9.4.5. Clinical Trials Information
9.4.6. Safety and Efficacy
9.4.7. Advantages and disadvantages
9.5. Myrcludex B: MYR Pharma
9.5.1. Drug Description
9.5.2. Product Profile
9.5.3. Other Development Activities
9.5.4. Clinical Development
9.5.5. Clinical Trials Information
9.5.6. Safety and efficacy
9.5.7. Advantages and disadvantages
9.6. Lonafarnib: Eiger BioPharmaceuticals
9.6.1. Drug Description
9.6.2. Product Profile
9.6.3. Regulatory milestones
9.6.4. Clinical Development
9.6.5. Clinical Trials Information
9.6.6. Safety and efficacy
9.6.7. Advantages and Disadvantages
9.7. Pegylated interferon lambda 1a: Eiger BioPharmaceuticals
9.7.1. Drug Description
9.7.2. Product Profile
9.7.3. Other development activities
9.7.4. Clinical Development
9.7.5. Clinical Trials Information
9.7.6. Safety and efficacy
9.7.7. Advantages and Disadvantages

10. Hepatitis D: Market Analysis

11. Key Findings
11.1. Hepatitis D: Total Market Size in 8MM
11.2. Total Market Size of Hepatitis D in 8MM
11.3. Therapy Based Market Size of Hepatitis D in 8MM

12. Market Size of Hepatitis D by Country
12.1. United States Market Analysis
12.1.1. Market Size of Hepatitis D in the US
12.1.2. Therapy Based Market Size of Hepatitis D in the US
12.2. Hepatitis D: EU5 Market Outlook
12.3. Germany
12.3.1. Market Size of Hepatitis D in Germany
12.3.2. Therapy Based Market Size of Hepatitis D in Germany
12.4. France
12.4.1. Market Size of Hepatitis D in France
12.4.2. Therapy Based Market Size of Hepatitis D in France
12.5. Italy
12.5.1. Market Size of Hepatitis D in Italy
12.5.2. Therapy Based Market Size of Hepatitis D in Italy
12.6. United Kingdom
12.6.1. Market Size of Hepatitis D in the UK
12.6.2. Therapy Based Market Size of Hepatitis D in the UK
12.7. Spain
12.7.1. Market Size of Hepatitis D in Spain
12.7.2. Therapy Based Market Size of Hepatitis D in Spain
12.8. Japan: Market Analysis
12.8.1. Market Size of Hepatitis D in Japan
12.8.2. Therapy Based Market Size of Hepatitis D in Japan
12.9. China: Market Analysis
12.9.1. Market Size of Hepatitis D in China
12.9.2. Therapy Based Market Size of Hepatitis D in China

13. Market Drivers of Hepatitis D

14. Market Barriers of Hepatitis D

15. Appendix

16. Report Methodology
16.1. Sources Used

17. Capabilities

18. Disclaimer

19. About the Publisher

List of Tables
Table 1: 8MM, Historical & Forecasted Hepatitis D Prevalence, 2016-2027
Table 2: the United States, Historical & Forecasted Hepatitis D Prevalence, 2016-2027
Table 3: the United States, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2027
Table 4: the United States, Gender-Specific Hepatitis D Prevalence, 2016-2027
Table 5: the United States, Age-Specific Hepatitis D Prevalence, 2016-2027
Table 6: the United States, Diagnosed cases of Hepatitis D, 2016-2027
Table 7: EU5, Historical & Forecasted Hepatitis D Prevalence, 2016-2027
Table 8: France, Historical & Forecasted Hepatitis D Prevalence, 2016-2027
Table 9: France, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2027
Table 10: France, Gender Specific Hepatitis D Prevalence, 2016-2027
Table 11: France, Age Specific Hepatitis D Prevalence, 2016-2027
Table 12: France, Diagnosed cases of Hepatitis D, 2016-2027
Table 13: Germany, Historical & Forecasted Hepatitis D Prevalence, 2016-2027
Table 14: Germany, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2027
Table 15: Germany, Gender-Specific Hepatitis D Prevalence, 2016-2027
Table 16: Germany, Age-Specific Hepatitis D Prevalence, 2016-2027
Table 17: Germany, Diagnosed cases of Hepatitis D, 2016-2027
Table 18: Italy, Historical & Forecasted Hepatitis D Prevalence, 2016-2027
Table 19: Italy, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2027
Table 20: Italy, Gender-Specific Hepatitis D Prevalence, 2016-2027
Table 21: Italy, Age-Specific Hepatitis D Prevalence, 2016-2027
Table 22: Italy, Diagnosed cases of Hepatitis D, 2016-2027
Table 23: Spain, Historical & Forecasted Hepatitis D Prevalence, 2016-2027
Table 24: Spain, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2027
Table 25: Spain, Gender Specific Hepatitis D Prevalence, 2016-2027
Table 26: Spain, Age Specific Hepatitis D Prevalence, 2016-2027
Table 27: Spain, Diagnosed cases of Hepatitis D, 2016-2027
Table 28: the United Kingdom, Historical & Forecasted Hepatitis D Prevalence, 2016-2027
Table 29: the United Kingdom, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2027
Table 30: the United Kingdom, Gender Specific Hepatitis D Prevalence, 2016-2027
Table 31: the United Kingdom, Age-Specific Hepatitis D Prevalence, 2016-2027
Table 32: the United Kingdom, Diagnosed cases of Hepatitis D, 2016-2027
Table 33: Japan, Historical & Forecasted Hepatitis D Prevalence, 2016-2027
Table 34: Japan, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2027
Table 35: Japan, Gender Specific Hepatitis D Prevalence, 2016-2027
Table 36: Japan, Age Specific Hepatitis D Prevalence, 2016-2027
Table 37: Japan, Diagnosed cases of Hepatitis D, 2016-2027
Table 38: China, Historical & Forecasted Hepatitis D Prevalence, 2016-2027
Table 39: China, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2027
Table 40: China, Gender Specific Hepatitis D Prevalence, 2016-2027
Table 41: China, Age Specific Hepatitis D Prevalence, 2016-2027
Table 42: China, Diagnosed cases of Hepatitis D, 2016-2027
Table 43: Phase I/II drug analysis
Table 44: Pegasys, Clinical Trial Description, 2018
Table 45: REP 2139, Clinical Trial Description, 2018
Table 46: Myrcludex B, Clinical Trial Description, 2018
Table 47: Lonafarnib, Clinical Trial Description, 2018
Table 48: Lambda, Clinical Trial Description, 2018
Table 49: 8 Major Market Size of Hepatitis D in USD Million (2016-2027)
Table 50: Therapy Based Market Size of Hepatitis D in 8MM in USD Million (2016-2027)
Table 51: Market Size of Hepatitis D in the US, USD Million (2016-2027)
Table 52: Therapy Based Market Size of Hepatitis D in the US in USD Million (2016-2027)
Table 53: Market Size of Hepatitis D in Germany, USD Million (2016-2027)
Table 54: Therapy Based Market Size of Hepatitis D in Germany in USD Million (2016-2027)
Table 55: Market Size of Hepatitis D in France, USD Million (2016-2027)
Table 56: Therapy Based Market Size of Hepatitis D in France in USD Million (2016-2027)
Table 57: Market Size of Hepatitis D in Italy, USD Million (2016-2027)
Table 58: Therapy Based Market Size of Hepatitis D in Italy in USD Million (2016-2027)
Table 59: Market Size of Hepatitis D in the UK, USD Million (2016-2027)
Table 60: Therapy Based Market Size of Hepatitis D in the UK in USD Million (2016-2027)
Table 61: Market Size of Hepatitis D in Spain, USD Million (2016-2027)
Table 62: Therapy Based Market Size of Hepatitis D in Spain in USD Million (2016-2027)
Table 63: Market Size of Hepatitis D in Japan, USD Million (2016-2027)
Table 64: Therapy Based Market Size of Hepatitis D in Japan in USD Million (2016-2027)
Table 65: Market Size of Hepatitis D in China, USD Million (2016-2027)
Table 66: Therapy Based Market Size of Hepatitis D in China in USD Million (2016-2027)

List of Figures
Figure 1: Hepatitis Delta Virus Structure
Figure 2: Pathogenesis of Hepatitis D
Figure 3: Diagnostic markers in various hepatitis D disease patterns
Figure 4: 8MM, Historical & Forecasted Hepatitis D Prevalence, 2016-2027
Figure 5: the United States, Historical & Forecasted Hepatitis D Prevalence, 2016-2027
Figure 6: the United States, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2027
Figure 7: the United States, Gender-Specific Hepatitis D Prevalence, 2016-2027
Figure 8: the United States, Age Specific Hepatitis D Prevalence, 2016-2027
Figure 9: the United States, Diagnosed cases of Hepatitis D, 2016-2027
Figure 10: EU5, Historical & Forecasted Hepatitis D Prevalence, 2016-2027
Figure 11: France, Historical & Forecasted Hepatitis D Prevalence, 2016-2027
Figure 12: France, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2027
Figure 13: France, Gender Specific Hepatitis D Prevalence, 2016-2027
Figure 14: France, Age-specific Hepatitis D Prevalence, 2016-2027
Figure 15: France, Diagnosed cases of Hepatitis D, 2016-2027
Figure 16: Germany, Historical & Forecasted Hepatitis D Prevalence, 2016-2027
Figure 17: Germany, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2027
Figure 18: Germany, Gender-Specific Hepatitis D Prevalence, 2016-2027
Figure 19: Germany, Age-Specific Hepatitis D Prevalence, 2016-2027
Figure 20: Germany, Diagnosed cases of Hepatitis D, 2016-2027
Figure 21: Italy, Historical & Forecasted Hepatitis D Prevalence, 2016-2027
Figure 22: Italy, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2027
Figure 23: Italy, Gender-Specific Hepatitis D Prevalence, 2016-2027
Figure 24: Italy, Age-Specific Hepatitis D Prevalence, 2016-2027
Figure 25: Italy, Diagnosed cases of Hepatitis D, 2016-2027
Figure 26: Spain, Historical & Forecasted Hepatitis D Prevalence, 2016-2027
Figure 27: Spain, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2027
Figure 28: Spain, Gender Specific Hepatitis D Prevalence, 2016-2027
Figure 29: Spain, Age Specific Hepatitis D Prevalence, 2016-2027
Figure 30: Spain, Diagnosed cases of Hepatitis D, 2016-2027
Figure 31: the United Kingdom, Historical & Forecasted Hepatitis D Prevalence, 2016-2027
Figure 32: the United Kingdom, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2027
Figure 33: the United Kingdom, Gender-Specific Hepatitis D Prevalence, 2016-2027
Figure 34: the United Kingdom, Age Specific Hepatitis D Prevalence, 2016-2027
Figure 35: the United Kingdom, Diagnosed cases of Hepatitis D, 2016-2027
Figure 36: Japan, Historical & Forecasted Hepatitis D Prevalence, 2016-2027
Figure 37: Japan, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2027
Figure 38: Japan, Gender Specific Hepatitis D Prevalence, 2016-2027
Figure 39: Japan, Age Specific Hepatitis D Prevalence, 2016-2027
Figure 40: Japan, Diagnosed cases of Hepatitis D, 2016-2027
Figure 41: China, Historical & Forecasted Hepatitis D Prevalence, 2016-2027
Figure 42: China, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2027
Figure 43: China, Gender Specific Hepatitis D Prevalence, 2016-2027
Figure 44: China, Age Specific Hepatitis D Prevalence, 2016-2027
Figure 45: China, Diagnosed cases of Hepatitis D, 2016-2027
Figure 46: Suggested Algorithm for Investigation and Treatment
Figure 47: Diagnosis and Treatment of Hepatitis Delta Virus (HDV) infection
Figure 48: Treatment algorithm
Figure 49: Unmet Needs of HDV
Figure 50: 8 Major Market Size of Hepatitis D in USD Million (2016-2027)
Figure 51: Therapy Based Market Size of Hepatitis D in 8MM in USD Million (2016-2027)
Figure 52: Market Size of Hepatitis D in the US, USD Million (2016-2027)
Figure 53: Therapy Based Market Size of Hepatitis D in the US in USD Million (2016-2027)
Figure 54: Market Size of Hepatitis D in Germany, USD Million (2016-2027)
Figure 55: Therapy Based Market Size of Hepatitis D in Germany in USD Million (2016-2027)
Figure 56: Market Size of Hepatitis D in France, USD Million (2016-2027)
Figure 57: Therapy Based Market Size of Hepatitis D in France in USD Million (2016-2027)
Figure 58: Market Size of Hepatitis D in Italy, USD Million (2016-2027)
Figure 59: Therapy Based Market Size of Hepatitis D in Italy in USD Million (2016-2027)
Figure 60: Market Size of Hepatitis D in the UK, USD Million (2016-2027)
Figure 61: Therapy Based Market Size of Hepatitis D in the UK in USD Million (2016-2027)
Figure 62: Market Size of Hepatitis D in Spain, USD Million (2016-2027)
Figure 63: Therapy Based Market Size of Hepatitis D in Spain in USD Million (2016-2027)
Figure 64: Market Size of Hepatitis D in Japan, USD Million (2016-2027)
Figure 65: Therapy Based Market Size of Hepatitis D in Japan in USD Million (2016-2027)
Figure 66: Market Size of Hepatitis D in China, USD Million (2016-2027)
Figure 67: Therapy Based Market Size of Hepatitis D in China in USD Million (2016-2027)
Figure 68: Market Drivers of HDV
Figure 69: Market Barriers of HDV
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Hoffmann-La Roche
  • Replicor Inc.
  • MYR Pharma
  • Eiger BioPharmaceuticals
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll